New Zealand’s Pharmac Mulls Amgevita Listing

Amgen’s Adalimumab Biosimilar Considered To Replace Humira As Principal Funded Brand

 
• By Dave Wallace
  
New Zealand Flag
New Zealand’s Pharmac is considering replacing Humira with Amgevita • Source: Alamy

More from Biosimilars

More from Products